Expand New Drugs for TB [endTB]

Partners in Health2,804 enrolled

Overview

This observational study will examine the safety and efficacy of bedaquiline and delamanid used (individually, not together) in routine, multidrug regimens for treatment of MDR-TB. The information gathered in this study will inform doctors how best to use these TB drugs in the future.

Study Type

OBSERVATIONAL

Enrollment

2,804

Conditions

Tuberculosis, Multidrug-Resistant

Interventions

This is a non-intervention observational studyOTHER

No applicable intervention; this is a secondary data analysis observational study.

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Any patient who receives a treatment regimen containing bedaquiline or delamanid at an endTB site will be invited to participate in this observational study, regardless of age or gender. * Any patient who signs the study informed consent form will be included in the study. Exclusion Criteria: * Refusal to participate in the study.

Locations (16)

National Treatment Centre for Tuberculosis, Abovian, Armenia

Abovyan, Armenia

National Institute of Diseases of the Chest and Hospital (NIDCH), Dhaka

Dhaka, Bangladesh

Outcomes

Primary Outcomes

End of treatment outcome

Final outcomes: cured, treatment completed, treatment failed, lost to follow-up, died, not evaluated

Time frame: 20 - 24 months of treatment

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.